relapsing remitting multiple sclerosis
Neurology · 2018–2018
1decision
1medicine
1carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| alemtuzumab Relapsing remitting multiple sclerosis (RRMS); specifically the resubmission sought reimbursement of up to two additional courses of treatment for patients… | Nov 2018 | Not recommended | input received MS Research Australia |
Who spoke
MS Research Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.